Immunome, Inc. (NASDAQ:IMNM) was the recipient of a significant decrease in short interest during the month of April. As of April 15th, there was short interest totalling 191,600 shares, a decrease of 19.0% from the March 31st total of 236,400 shares. Currently, 2.4% of the shares of the company are sold short. Based on an average daily trading volume, of 280,700 shares, the short-interest ratio is currently 0.7 days.

Separately, Zacks Investment Research upgraded Immunome from a “hold” rating to a “buy” rating and set a $30.00 price objective on the stock in a research report on Tuesday.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Strs Ohio purchased a new position in shares of Immunome during the 1st quarter worth $47,000. New York State Common Retirement Fund purchased a new position in shares of Immunome during the 4th quarter worth $53,000. JPMorgan Chase & Co. purchased a new position in shares of Immunome during the 4th quarter worth $55,000. Northern Trust Corp purchased a new position in shares of Immunome during the 4th quarter worth $245,000. Finally, Granite Point Capital Management L.P. purchased a new position in shares of Immunome during the 4th quarter worth $645,000.

Shares of IMNM traded down $0.64 during midday trading on Tuesday, reaching $24.42. The company had a trading volume of 69,754 shares, compared to its average volume of 243,311. Immunome has a 1-year low of $9.27 and a 1-year high of $63.78. The firm has a 50 day simple moving average of $30.08 and a 200-day simple moving average of $20.04.

Immunome (NASDAQ:IMNM) last issued its earnings results on Wednesday, March 24th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.11). As a group, equities analysts anticipate that Immunome will post -2.32 earnings per share for the current fiscal year.

About Immunome

Immunome, Inc, a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19.

See Also: When can a hold rating present a buying opportunity?

Receive News & Ratings for Immunome Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunome and related companies with MarketBeat.com's FREE daily email newsletter.